Additional Disclosure Information, Annual, 2017, BDPT

This information is additional information to be included as part of the 2017 Annual Disclosure Document for BioAdaptives, Inc.

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

Preferred Stock – The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of December 31, 2017, and 2016, no shares of preferred stock had been issued.

Common Stock – The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock. As of December 31, 2017, and 2016, there were 15,578,262 and 14,180,456 shares of the Company's common stock issued and outstanding, respectively.

On October 3, 2017, the Company issued 1,197,806 shares of common stock to Ferris Holding, Inc. a common control entity for the settlement of debt valued at $203,627.

On October 3, 2017, the Company issued 200,000 shares of common stock to 2 unrelated parties for services valued at $34,000.

On February 15, 2016, the Company issued 1,444,020 shares of common stock to Ferris Holding, Inc. a common control entity for the purchase of inventory valued at $144,402.

In the year ended December 31, 2015, the Company issued 100,000 shares of common stock to its chief executive officer, Christopher G. Hall, as compensation for two years of services to be performed pursuant to an employment agreement dated February 6, 2015. The Company valued the 100,000 shares of common stock on the date of the agreement, $1.10 per share, which resulted in a total consideration of $110,050 which will be expensed throughout the two-year term of the employment agreement. For the three months ended March 31, 2017 and 2016, the Company expensed $5,182 and $13,719, respectively.